acr-2316
·Code: ACR-2316
acr-2316: sourced relationships with 1 company · 1 clinical trial tracked.
acr-2316 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect acr-2316 to ACRV; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could acr-2316 → ACRV affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Specific Advanced Solid Tumors
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Acrivon Therapeutics, Inc. (ACRV) Specific Advanced Solid Tumors | Phase 2 |
Clinical Trial Registry Records (1)
ACR-2316-101: Phase 1/2 Study of ACR-2316 in Subjects With Advanced Solid Tumors
Primary endpoint: Dose Escalation
InterventionalRandomizedopen100 targetStarted 2024-10Completion 2027-1215 sites · United StatesAcrivon Therapeutics
Frequently asked questions
Which companies have sourced relationships with acr-2316?
acr-2316 has dated SEC/FDA relationship records for Acrivon Therapeutics, Inc..
How many clinical trials involve acr-2316?
BioSniper tracks 1 clinical trial involving acr-2316.